Vanderbilt Vaccine Center

Researchers at Vanderbilt University Medical Center, Purdue University and the University of Wisconsin-Madison have isolated human monoclonal antibodies that potentially can prevent a rare but devastating polio-like illness in children linked to a respiratory viral infection. Read More

From the front lines of patient care to collaborating with scientists across the globe searching for treatments and vaccines, Vanderbilt University Medical Center and Vanderbilt University researchers have been working for months to combat the COVID-19 pandemic. Read More

Vanderbilt Vaccine Center team isolates monoclonal antibodies against the mosquito-borne Ross River virus, which causes rash, fever and debilitating muscle and joint pain lasting three to six months. Read More

Monoclonal antibodies against Marburg virus — a more lethal cousin of the RNA virus that causes COVID-19 — may aid in the development of antibody "cocktails" to counter viral infection. Read More

Vanderbilt University Medical Center is teaming up with academic, governmental and corporate partners in an unprecedented, fast-tracked global effort to develop antibody-based treatments to protect people exposed to the 2019 novel coronavirus disease, COVID-19. Read More

A research team led by scientists at Vanderbilt University Medical Center has developed an antibody mixture that in animals is highly effective in blocking infection by the Ebola virus. Read More

VUMC scientists are redoubling their efforts to help people fight off bird flu. Their focus is H7N9, one of the most dangerous of the influenza viruses that have been transmitted from birds to humans. Read More

Antibody discovery and vaccine development research may be on the verge of rapidly expanding with data that previously took decades to acquire, thanks to LIBRA-seq, a new tool developed by Vanderbilt University researchers and their colleagues. Read More

Researchers at Vanderbilt University Medical Center are partnering with the Dutch biopharmaceutical firm Batavia Biosciences and Nashville-based IDBiologics to bring to the clinic a highly potent Zika virus neutralizing antibody they isolated three years ago. Read More

James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, will be honored today by the science and technology company Merck KGaA, Darmstadt, Germany for his contributions to developing new therapeutics and vaccines against some of the world’s deadliest viruses. Read More

Scientists are testing a new way to fight chikungunya virus that involves injecting genetic material into the bodies of infected and at-risk individuals to trigger rapid production of potent, virus-neutralizing antibodies. Read More

VUMC has joined an international effort to streamline and accelerate development of vaccines and other treatments against a growing worldwide surge of deadly and debilitating viral infections. Read More

The flu mutates so quickly that we need a new vaccine every year, but Vanderbilt scientists have found a vulnerable part of the virus that doesn't mutate as much. Read More

The Vanderbilt Vaccine Center Seminar Series presents Brandon DeKosky, assistant professor of chemical engineering and pharmaceutical chemistry at the University of Kansas, on Monday, May 6. Read More

A monoclonal antibody against the chikungunya virus developed by researchers at Vanderbilt University Medical Center is the first monoclonal antibody encoded by messenger RNA to enter a clinical trial. Read More

Using sophisticated gene sequencing and computing techniques, Vanderbilt researchers have achieved a first-of-its-kind glimpse into how the body’s immune system gears up to fight off infection. Read More

James Crowe Jr. and colleagues have developed a new computational method that may allow researchers to develop flu antibodies that can protect against more strains of the disease. Read More

Scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis are racing to develop — in a mere 90 days — a protective antibody-based treatment that can stop the spread of the Zika virus. Read More

Research led by James Crowe, Jr., could lead to the first effective treatment for this dangerous mosquito-transmitted infection. Read More

The discovery of these antibodies could significantly improve the diagnosis and treatment of the leading cause of stomach illness in the world. Read More